Navigation Links
Single gene mutation induces endometrial cancer
Date:2/9/2010

DALLAS Feb. 10, 2010 A mutation in a single gene can cause endometrial cancer that is responsive to a specific drug therapy, researchers at UT Southwestern Medical Center have found in an animal study.

The finding suggests that eventually it might be possible to screen women with endometrial cancer to see if they have that mutation and use the drug as targeted therapy, the researchers said.

"Our data suggest that deficiency of this gene can indicate both how aggressive an endometrial tumor will be and how well it might respond to a specific class of drugs," said Dr. Diego Castrillon, assistant professor of pathology at UT Southwestern and senior author of the paper, which appears in the March/April issue of Disease Models and Mechanisms.

"Some early clinical trials have shown that about one-fifth of women with endometrial cancers respond to a group of drugs called 'rapalogs,'" Dr. Castrillon said. "Unfortunately, it is not currently possible to predict which women these are."

Endometrial cancer affects the lining of the uterus. This cancer is the most common cancer of the female reproductive tract and is usually detected when a woman complains of excessive bleeding. About one-third of ovarian cancer cases are believed to begin as endometrial cancer, Dr. Castrillon said. The median survival of women with advanced endometrial cancer is one year.

The researchers focused the gene Lkb1, which is known to suppress other types of cancers. Mutations in Lkb1 disrupt its "braking" action on cancer and contribute to the disease in lungs, skin and other tissues.

In the current study, the researchers genetically engineered mice to inactive Lkb1 only in the endometrium. Without Lkb1, the entire endometrium became cancerous early and rapidly, they found.

The researchers found that treating the cancerous mice with the anti-cancer drug rapamycin slowed the progression of the cancers and dramatically shrank existing tumors.

"We hope that someday a test based on this gene or others like it might pinpoint which women would respond best to treatment with 'rapalogs,'" Dr. Castrillon said. "Such personalized medicine could spare other women from unnecessary chemotherapy if their tumors are unresponsive to the drugs."

Other UT Southwestern researchers participating in the study were graduate students Cristina Contreras and Esra Akbay; senior research scientist Teresa Gallardo; research assistant Marshall Haynie; Dr. Masaya Takahashi, associate professor in UT Southwestern's Advanced Imaging Research Center; and Dr. Osamu Togao, postdoctoral research fellow in the Advanced Imaging Research Center.

Researchers at Harvard Medical School also participated in the study.

The research was supported by the National Cancer Institute, a Translational Science Award from the Sidney Kimmel Foundation for Cancer Research, the American Cancer Society, and the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern.


'/>"/>
Contact: Aline McKenzie
aline.mckenzie@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
2. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
3. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
4. Gene profiling can single out the worst cases of multiple myeloma and guide therapy
5. International Watchdog Group Singles Out Resurrection for Anti-Union Violations
6. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
7. Married esophageal cancer patients fare worse in some quality of life aspects than single patients
8. Verathon Inc. Introduces GlideScope(R) Ranger Single Use Video Laryngoscope for Emergency Departments, EMS and Military; Enables Fast Intubations and Eliminates Time-Consuming Disinfection
9. National Nurses Movement Lauds Al Gore for Leadership on Single-Payer Healthcare
10. Methodist Health System Foundation Announces Largest Single Gift
11. Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. , ... a development collaboration with the Australian critical medicine company, Phebra Pty Ltd. ... , LAI medicines can offer improved therapeutic benefits over oral formulations, including better ...
(Date:5/5/2016)... ... May 05, 2016 , ... The ... electronic cigarettes, requiring e-cigarette manufacturers to submit their products through an arduous federal ... all vaping products that entered the market since February 15, 2007. That would ...
(Date:5/5/2016)... FL (PRWEB) , ... May 05, 2016 , ... ... in Tampa to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to ... Implant. Since first offering the procedure in April of 2015, Florida Hospital Pepin ...
(Date:5/5/2016)... ... May 05, 2016 , ... This weekend, from Friday, May 6 - Sunday, May 8, ... terrain at the first Team Semper Fi Mountain Bike Camp, hosted in conjunction with ... bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with the injured veterans ...
(Date:5/5/2016)... ... 2016 , ... Phycologia – While it is ... researchers Juntian Xu and Kunshan Gao tested the magnitude of this phenomenon on ... photosynthetically active radiation (i.e. the white light in our visible spectrum) was not ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 Research and ... Acute lymphocytic Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic ...
(Date:5/3/2016)... DUBLIN , May 4, 2016 ... the "Global Cancer Stem Cell Therapy Market Outlook ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has ... therapeutics are expected to be developed in coming years. ... these techniques. Cancer stem cell therapies are also expected ...
(Date:5/3/2016)... , May 3, 2016 ACME ... Whelan and Delaware County Councilman ... Nasal Spray in all ACME pharmacies across ... for Disease Control and Prevention (CDC), naloxone has saved 26,463 lives ... officers in Delaware County were authorized to ...
Breaking Medicine Technology: